Ke Zu1, Lorelei Mucci, Bernard A Rosner, Steven K Clinton, Massimo Loda, Meir J Stampfer, Edward Giovannucci. 1. Affiliations of authors: Department of Nutrition (KZ, MJS, EG), Department of Epidemiology (LM, MJS, EG), and Department of Biostatistics (BAR), Harvard School of Public Health, Boston, MA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (LM, BAR, MJS, EG); Department of Internal Medicine, The Ohio State University, Columbus, OH (SKC); Department of Pathology, Dana-Farber Cancer Institute, Boston, MA (ML).
Abstract
BACKGROUND: The role of lycopene in prostate cancer prevention remains controversial. We examined the associations between dietary lycopene intake and prostate cancer, paying particular attention to the influence of prostate-specific antigen screening, and evaluated tissue biomarkers in prostate cancers in relation to lycopene intake. METHODS: Among 49898 male health professionals, we obtained dietary information through questionnaires and ascertained total and lethal prostate cancer cases from 1986 through January 31, 2010. Cox regression was used to estimate multivariable hazard ratios (HRs) and 95% confidence intervals (CIs). Tissue microarrays and immunohistochemistry were used to assess tumor biomarker expression in a subset of men. Two-sided χ(2) tests were used to calculate the P values. RESULTS: Higher lycopene intake was inversely associated with total prostate cancer and more strongly with lethal prostate cancer (top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04). In a restricted population of screened participants, the inverse associations became markedly stronger (for lethal prostate cancer: HR = 0.47; 95% CI = 0.29 to 0.75; P trend = .009). Comparing different measures of dietary lycopene, early intake, but not recent intake, was inversely associated with prostate cancer. Higher lycopene intake was associated with biomarkers in the cancer indicative of less angiogenic potential. CONCLUSIONS: Dietary intake of lycopene was associated with reduced risk of lethal prostate cancer and with a lesser degree of angiogenesis in the tumor. Because angiogenesis is a strong progression factor, an endpoint of lethal prostate cancer may be more relevant than an endpoint of indolent prostate cancer for lycopene in the era of highly prevalent prostate-specific antigen screening.
BACKGROUND: The role of lycopene in prostate cancer prevention remains controversial. We examined the associations between dietary lycopene intake and prostate cancer, paying particular attention to the influence of prostate-specific antigen screening, and evaluated tissue biomarkers in prostate cancers in relation to lycopene intake. METHODS: Among 49898 male health professionals, we obtained dietary information through questionnaires and ascertained total and lethal prostate cancer cases from 1986 through January 31, 2010. Cox regression was used to estimate multivariable hazard ratios (HRs) and 95% confidence intervals (CIs). Tissue microarrays and immunohistochemistry were used to assess tumor biomarker expression in a subset of men. Two-sided χ(2) tests were used to calculate the P values. RESULTS: Higher lycopene intake was inversely associated with total prostate cancer and more strongly with lethal prostate cancer (top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04). In a restricted population of screened participants, the inverse associations became markedly stronger (for lethal prostate cancer: HR = 0.47; 95% CI = 0.29 to 0.75; P trend = .009). Comparing different measures of dietary lycopene, early intake, but not recent intake, was inversely associated with prostate cancer. Higher lycopene intake was associated with biomarkers in the cancer indicative of less angiogenic potential. CONCLUSIONS: Dietary intake of lycopene was associated with reduced risk of lethal prostate cancer and with a lesser degree of angiogenesis in the tumor. Because angiogenesis is a strong progression factor, an endpoint of lethal prostate cancer may be more relevant than an endpoint of indolent prostate cancer for lycopene in the era of highly prevalent prostate-specific antigen screening.
Authors: Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Edward Giovannucci; Eric B Rimm; Yan Liu; Meir J Stampfer; Walter C Willett Journal: J Natl Cancer Inst Date: 2002-03-06 Impact factor: 13.506
Authors: T M Vogt; S T Mayne; B I Graubard; C A Swanson; A L Sowell; J B Schoenberg; G M Swanson; R S Greenberg; R N Hoover; R B Hayes; R G Ziegler Journal: Am J Epidemiol Date: 2002-06-01 Impact factor: 4.897
Authors: Ke Zu; Neil E Martin; Michelangelo Fiorentino; Richard Flavin; Rosina T Lis; Jennifer A Sinnott; Stephen Finn; Kathryn L Penney; Jing Ma; Ladan Fazli; Martin E Gleave; Tarek A Bismar; Meir J Stampfer; Michael N Pollak; Massimo Loda; Lorelei A Mucci; Edward Giovannucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-08-27 Impact factor: 4.254
Authors: Erin L Van Blarigan; John P Gerstenberger; June M Chan; Lorelei A Mucci; Stacey A Kenfield; Edward L Giovannucci; Meir J Stampfer; Lee W Jones; Steven K Clinton Journal: Cancer Prev Res (Phila) Date: 2015-08-14
Authors: Juan Wu; Kathryn M Wilson; Meir J Stampfer; Walter C Willett; Edward L Giovannucci Journal: Int J Cancer Date: 2018-01-23 Impact factor: 7.396
Authors: Nancy E Moran; Jennifer M Thomas-Ahner; Jessica L Fleming; Joseph P McElroy; Rebecca Mehl; Elizabeth M Grainger; Ken M Riedl; Amanda E Toland; Steven J Schwartz; Steven K Clinton Journal: J Nutr Date: 2019-03-01 Impact factor: 4.798
Authors: Samuel O Antwi; Susan E Steck; L Joseph Su; James R Hebert; Hongmei Zhang; Neal E Craft; Elizabeth T H Fontham; Gary J Smith; Jeannette T Bensen; James L Mohler; Lenore Arab Journal: Prostate Date: 2016-06-08 Impact factor: 4.104
Authors: Joe L Rowles; Joshua W Smith; Catherine C Applegate; Rita J Miller; Matthew A Wallig; Amandeep Kaur; Jesus N Sarol; Salma Musaad; Steven K Clinton; William D O'Brien; John W Erdman Journal: J Nutr Date: 2020-07-01 Impact factor: 4.798
Authors: J Kellogg Parsons; John P Pierce; James Mohler; Electra Paskett; Sin-Ho Jung; Michael J Morris; Eric Small; Olwen Hahn; Peter Humphrey; John Taylor; James Marshall Journal: BJU Int Date: 2017-05-21 Impact factor: 5.588